CN101454324A - 吡啶并[3，2-e]吡嗪类化合物及其作为磷酸二酯酶10抑制剂的用途和制备方法 - Google Patents

吡啶并[3，2-e]吡嗪类化合物及其作为磷酸二酯酶10抑制剂的用途和制备方法 Download PDF

Info

Publication number
CN101454324A
CN101454324A CNA2007800193040A CN200780019304A CN101454324A CN 101454324 A CN101454324 A CN 101454324A CN A2007800193040 A CNA2007800193040 A CN A2007800193040A CN 200780019304 A CN200780019304 A CN 200780019304A CN 101454324 A CN101454324 A CN 101454324A
Authority
CN
China
Prior art keywords
pyrido
pyrazine
imidazo
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800193040A
Other languages
English (en)
Chinese (zh)
Inventor
N·霍夫根
H·斯坦格
B·兰根
U·埃格兰德
R·欣德勒
T·普费弗
C·伦德费尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elbion GmbH
Original Assignee
Elbion GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion GmbH filed Critical Elbion GmbH
Publication of CN101454324A publication Critical patent/CN101454324A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2007800193040A 2006-05-30 2007-05-29 吡啶并[3，2-e]吡嗪类化合物及其作为磷酸二酯酶10抑制剂的用途和制备方法 Pending CN101454324A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80924206P 2006-05-30 2006-05-30
US60/809,242 2006-05-30

Publications (1)

Publication Number Publication Date
CN101454324A true CN101454324A (zh) 2009-06-10

Family

ID=38441604

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800193040A Pending CN101454324A (zh) 2006-05-30 2007-05-29 吡啶并[3，2-e]吡嗪类化合物及其作为磷酸二酯酶10抑制剂的用途和制备方法

Country Status (21)

Country Link
US (2) US7550465B2 (https=)
EP (1) EP2021342A1 (https=)
JP (1) JP2009538853A (https=)
KR (1) KR20090013834A (https=)
CN (1) CN101454324A (https=)
AR (1) AR061206A1 (https=)
AU (1) AU2007267392A1 (https=)
BR (1) BRPI0712132A2 (https=)
CA (1) CA2651849A1 (https=)
CL (1) CL2007001554A1 (https=)
CR (1) CR10358A (https=)
GT (1) GT200800265A (https=)
IL (1) IL193740A0 (https=)
MX (1) MX2008014569A (https=)
NO (1) NO20085326L (https=)
PE (1) PE20080711A1 (https=)
RU (1) RU2008152440A (https=)
SV (1) SV2009003048A (https=)
TW (1) TW200817400A (https=)
WO (1) WO2007137820A1 (https=)
ZA (1) ZA200807517B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428302A (zh) * 2012-07-31 2015-03-18 勃林格殷格翰国际有限公司 4-甲基-2,3,5,9,9b-五氮杂-环戊二烯并[a]萘
CN104684912A (zh) * 2012-08-17 2015-06-03 艾伯维德国有限责任两合公司 磷酸二酯酶10a型的抑制剂化合物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US8299080B2 (en) 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
US20090143392A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
KR20100110804A (ko) * 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
CN102065861B (zh) * 2008-05-07 2013-10-16 H.隆德贝克有限公司 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
WO2010054253A1 (en) * 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
TWI520949B (zh) * 2010-07-20 2016-02-11 錫蘭尼克藥物有限公司 使用環醯胺衍生物治療σ受體介導之病症的方法
RS64819B1 (sr) * 2010-07-20 2023-12-29 Minerva Neurosciences Inc Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
CA2827724A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
EP2763989A1 (en) * 2011-09-09 2014-08-13 H. Lundbeck A/S Pyridine compounds and uses thereof
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
SG11201402134VA (en) 2011-11-09 2014-06-27 Abbvie Deutschland Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a
NZ631258A (en) 2012-04-25 2016-11-25 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
WO2014010732A1 (ja) * 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
WO2014041175A1 (en) 2012-09-17 2014-03-20 Abbott Gmbh & Co. Kg Novel inhibitor compounds of phosphodiesterase type 10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2970258B1 (en) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Novel inhibitor compounds of phosphodiesterase type 10a
EP3018123B1 (en) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amide compound
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CN108473495B (zh) 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
IL319156A (en) 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
EP3856185A1 (en) 2018-09-28 2021-08-04 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
CN114524808B (zh) * 2022-02-21 2023-10-24 深圳市儿童医院 一种吡唑衍生物及其作为pde10抑制剂的用途
CN114524806B (zh) * 2022-02-22 2024-09-03 深圳市儿童医院 一种三氮唑衍生物及其作为pde10抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
KR100207360B1 (ko) * 1991-06-14 1999-07-15 돈 더블유. 슈미츠 이미다조[1,5,-a]퀸옥살린
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104428302A (zh) * 2012-07-31 2015-03-18 勃林格殷格翰国际有限公司 4-甲基-2,3,5,9,9b-五氮杂-环戊二烯并[a]萘
CN104428302B (zh) * 2012-07-31 2017-03-22 勃林格殷格翰国际有限公司 4‑甲基‑2,3,5,9,9b‑五氮杂‑环戊二烯并[a]萘
CN104684912A (zh) * 2012-08-17 2015-06-03 艾伯维德国有限责任两合公司 磷酸二酯酶10a型的抑制剂化合物

Also Published As

Publication number Publication date
MX2008014569A (es) 2008-12-03
PE20080711A1 (es) 2008-06-14
IL193740A0 (en) 2009-05-04
US20090239874A1 (en) 2009-09-24
US20080027064A1 (en) 2008-01-31
CA2651849A1 (en) 2007-12-06
CL2007001554A1 (es) 2008-01-18
CR10358A (es) 2009-01-07
EP2021342A1 (en) 2009-02-11
NO20085326L (no) 2008-12-19
SV2009003048A (es) 2009-02-11
RU2008152440A (ru) 2010-07-10
AR061206A1 (es) 2008-08-13
TW200817400A (en) 2008-04-16
KR20090013834A (ko) 2009-02-05
JP2009538853A (ja) 2009-11-12
GT200800265A (es) 2010-07-22
AU2007267392A1 (en) 2007-12-06
US7550465B2 (en) 2009-06-23
WO2007137820A1 (en) 2007-12-06
BRPI0712132A2 (pt) 2012-01-17
ZA200807517B (en) 2009-06-24

Similar Documents

Publication Publication Date Title
CN101454324A (zh) 吡啶并[3，2-e]吡嗪类化合物及其作为磷酸二酯酶10抑制剂的用途和制备方法
JP2009538852A (ja) ４−アミノ−ピリド［３，２−ｅ］ピラジン、該化合物のホスホジエステラーゼ１０の阻害剤としての使用、及び該化合物の製造方法
US20090143391A1 (en) Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
JP5698761B2 (ja) 酵素ｐｄｅ１０ａ阻害剤としての２−アリールイミダゾール誘導体
EP3663296B1 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
US7875618B2 (en) Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
US20090143361A1 (en) Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
US20090143392A1 (en) Methods of Treating Obesity and Metabolic Disorders
JP2013505911A (ja) ホスホジエステラーゼ１０ａ阻害剤としてのイミダゾピリジンまたはイミダゾピリミジン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090610